Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | APAF1 | O14727 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8088015 | 0.77 | SRD5A2 (0.33) | KDM4EMEN1APAF1LMNAMAPT | |
| SCHEMBL8090185 | 0.75 | KDM4E (0.31) | KDM4EMEN1APAF1LMNAMAPT | |
| SCHEMBL3709921 | 0.74 | CYP1A2 (0.36) | MAPT | |
| SCHEMBL4338458 | 0.71 | — | — | |
| SCHEMBL15966508 | 0.62 | FPR2 (0.35) | KDM4EMEN1APAF1LMNAMAPT | |
| SCHEMBL17596363 | 0.61 | HDAC3 (0.36) | MEN1LMNAMAPTKMT2A | |
| SCHEMBL16240606 | 0.61 | CYP1A2 (0.33) | — | |
| SCHEMBL24894331 | 0.60 | — | — | |
| SCHEMBL30803855 | 0.60 | — | — | |
| SCHEMBL24894338 | 0.60 | ATM (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010087761-A1 | 2-AZA-BICYCLO[2.2.2]OCTANE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2010-08-05 | — | — | WO | disclosed |
| US-20090030033-A1 | Novel Compounds 894 | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| US-20090030033-A1 | Novel Compounds 894 | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| US-20090030033-A1 | Novel Compounds 894 | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| WO-2009013535-A1 | 2-AZABICYCLO(2.2.2)OCTANE DERIVATIVES AS MODULATORS OF THE GLYCINE TRANSPORTER I RECEPTOR | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030033-A1 | Novel Compounds 894 | AZI2, TPMT, AMPD2 | KDM4E 621/4885MEN1 3176/4885APAF1 3615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.